OpenAlex
PricingAboutJobs
Log inGet started
Author

M. Asayama

Institution: Saitama Cancer Center
Observed institution: Saitama Cancer Center
ORCID: 0009-0007-2763-1661
Observed ORCID: 0009-0007-2763-1661
OpenAlex ID: A5041246531
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
2024 · T. Sakakida, T. Masuishi, et al. · ESMO Gastrointestinal Oncology · 4
PDF
446TiP Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
2022 · K. Yamazaki, H. Satake, et al. · Annals of Oncology · 2
770P Impact of ctDNA testing on decision-making for adjuvant chemotherapy in colorectal cancer: A prospective multicenter study
2025 · S. Fukuoka, H. Osumi, et al. · Annals of Oncology
528P The randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): 1-year follow-up updated data from JCOG2014 (ROBiTS)
2024 · Y. Suwa, H. Satake, et al. · Annals of Oncology
PDF
Works count: 4
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms